Novo Nordisk A/S: Anemia, Sickle Cell trials

The registry lists 11 Anemia, Sickle Cell studies with Novo Nordisk A/S as lead sponsor. 4 are open to participants now and 0 have results posted.

Phase 1 3Phase 2 5Phase 3 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell DiseaseRecruitingNCT06612268Phase 3
• A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or ThalassaemiaRecruitingNCT06609226Phase 3
• A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell DiseaseRecruitingNCT06198712Phase 2
• A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary StrokeRecruitingNCT05953584Phase 2
• A Study on the Effect of Etavopivat on Heart Rhythm in Healthy ParticipantsCompletedNCT07023029Phase 1
• A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese ParticipantsCompletedNCT06581627Phase 1
• Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell DiseaseCompletedNCT05725902Phase 2
• Research Study Investigating How Well NDec Works in People With Sickle Cell DiseaseCompletedNCT05405114Phase 2
• A Study of Etavopivat in Patients With Thalassemia or Sickle Cell DiseaseCompletedNCT04987489Phase 2
• A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)Active, not recruitingNCT04624659Phase 3
• A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease PatientsCompletedNCT03815695Phase 1